MENLO PARK, Calif., June 29, 2015 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that Lisa Earnhardt, President and Chief Executive Officer of Intersect ENT (NASDAQ: XENT), has been appointed to its Board of Directors, effective June 28, 2015.
For the last seven years, Lisa Earnhardt has successfully led Intersect ENT, a company dedicated to improving the quality of life for patients with ear, nose and throat conditions. Prior to joining Intersect ENT, Ms. Earnhardt was the President of Boston Scientific's Cardiac Surgery division. In addition, Ms. Earnhardt held a variety of sales and marketing roles of increasing responsibility at Guidant, a leader in cardiovascular medical devices, leading global product launches and driving adoption of new technologies. Ms. Earnhardt served on the board of directors of Kensey Nash, a publicly traded company until it was acquired by Royal DSM NA in 2012, where she served on the board's nominating and governance and audit committees.
"We are pleased to be adding Lisa to our board. She is a medical device industry leader who has had her own recent success with Intersect ENT's IPO and subsequent financing," said Michael DeMane, Chairman and Chief Executive Officer. "Her experience in driving adoption of innovative medical technologies and sales and marketing expertise will add great value as we continue to execute on our launch in the U.S."
"I am delighted to join an organization that so highly values clinical evidence and is focused on improving patients' lives," said Ms. Earnhardt. "Nevro continues to differentiate itself in the spinal cord stimulation field, and I look forward to providing new insight as the company continues to grow and build out its business."
In connection with Ms. Earnhardt's appointment, Nathan B. Pliam, MD, PhD, Venture Partner at Bay City Capital, stepped off the Board of Directors at Nevro. "Nick has been an integral part of Nevro since its early days," said Michael DeMane, Chairman and Chief Executive Officer. "We are thankful for his contributions as a veteran in the venture space and medical device investment leader."
Headquartered in Menlo Park, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro.
Investor Relations Contact:
SOURCE Nevro Corp.